Orchard Therapeutics PLC (ORTX) Received its Third Buy in a Row
After Oppenheimer and Barclays gave Orchard Therapeutics PLC (NASDAQ: ORTX) a Buy rating last month, the company received another Buy, this time from Cowen & Co. Analyst Yaron Werber maintained a Buy rating on Orchard Therapeutics PLC today and set a price target of $28. The company’s shares closed last Monday at $15.03.
According to TipRanks.com, Werber is a 4-star analyst with an average return of 9.6% and a 58.6% success rate. Werber covers the Healthcare sector, focusing on stocks such as Ultragenyx Pharmaceutical, Inc., Rocket Pharmaceuticals Inc, and Prevail Therapeutics Inc.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Orchard Therapeutics PLC with a $24.67 average price target, implying a 72.9% upside from current levels. In a report issued on September 5, Barclays also initiated coverage with a Buy rating on the stock with a $21 price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $21.64 and a one-year low of $8.65. Currently, Orchard Therapeutics PLC has an average volume of 200.3K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Orchard Therapeutics Plc is a biopharmaceutical company, which engages in the discovery, acquisition, development, and commercialization of gene therapies. The company focuses on its autologous ex vivo gene therapy approach on three therapeutic rare disease franchise areas: primary immune deficiencies, neurometabolic disorders, and hemoglobinopathies.